EN DE
Watch Vyome Holdings for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Vyome Holdings (HIND) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Vyome Holdings stock $1.04, price $1.53, that is 32.0% below the price, quality 22 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US92943X1046

VH Vyome Holdings logo Thin data Nov 15, 2026

Vyome Holdings

HIND · US

Expensive (fair value 32% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Generates free cash flow over the last twelve months 
Recent news mostly positive 
Costs just 0.9 times its yearly profit. 
Fair value $1.04 · Overvalued 
Quality 22/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −51.0 %/yr in USD) 
Trails peers (2/8) 
Narrow moat 9/100
Thin data 
Estimate
Watch Vyome Holdings for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1,000,000 $1.53 Fair Value $1.04 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range $1.53 – $1,000,000 · fair‑value band $0.7800 – $1.30 · the $1.53 price screens above the $1.04 fair value. As of Nov 15, 2026.

Follow Vyome in your weekly email

Every Wednesday you see whether Vyome is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.

Show moreShow less

The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis.

It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne.

In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products.

The company is based in Cambridge, Massachusetts.

Stock analysis

Vyome Holdings (HIND) currently trades at $1.53, while our estimate is $1.04, 32% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.7800 (bear) to $1.30 (bull), the price of $1.53 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Vyome Holdings reported revenue of $320K in FY2025 versus $13.6M in FY2021, a compound −60.8%/yr. Reported net income was −$10.3M in FY2025.

Key figures

Market cap $10.7M Micro · P/E ratio 0.9 · P/S ratio 72.4 · EPS (TTM) $1.78 · Return on equity −74.8% · Return on assets (EBIT) −138% (5-year average) · Operating margin −2,854% · Revenue (TTM) $153K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 73% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −32%, HIND screens richer than that median.

Fair Value

Bear $0.7800 Fair Value $1.04 Bull $1.30
Price $1.53 · Downside -32.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 22/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 13
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 44
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−96.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−69.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−51.0%
Start year 2020 (pandemic). Over 10 years: +0.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−110.2% (2020) → −859.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

HIND screens overvalued: fair value 32% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (10 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Vyome Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −32.0% · Below median
Profitability
Return on assets −158.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 67.5% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 0.9× · Cheapest 25%
P/B 4.40× · Pricier than median
P/S (12 months) 70.14× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs HIND
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs HIND
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs HIND
argenx SE ARGX $950.95 $908.40 −4% vs HIND
CSL Limited CSL A$199.55 A$186.49 −7% vs HIND
Moderna, Inc MRNA $215.27 $135.64 −37% vs HIND
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs HIND
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs HIND
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs HIND
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs HIND

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vyome Holdings: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vyome Holdings Fair Value". https://www.fairvalue-calculator.com/stock/HIND

Frequently asked questions

Is Vyome Holdings (HIND) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is $1.04 versus a price of $1.53, about 32% lower (overvalued).
What is the fair value of HIND?
Our estimate for Vyome Holdings is $1.04 (as of Nov 15, 2026), built from audited fundamentals. The current price: $1.53.
What is the quality score of HIND?
Vyome Holdings has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vyome Holdings (HIND)?
Our calculated price target is the estimate of $1.04 (as of Nov 15, 2026). Cautious scenario $0.7800, optimistic scenario $1.30. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Vyome Holdings stock forecast for 2026?
Our estimate puts fair value at $1.04, about 32% lower versus a price of $1.53 (overvalued). Cautious scenario $0.7800, optimistic scenario $1.30. The calculation is refreshed regularly with new filings.
What is the revenue of Vyome Holdings (HIND)?
Vyome Holdings reported trailing-twelve-month revenue of about $153K (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Vyome Holdings (HIND)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vyome Holdings it is $1.04 per share (as of Nov 15, 2026), against a price of $1.53.
Is Vyome Holdings stock overvalued or undervalued in 2026?
As of Nov 15, 2026, HIND trades above its calculated fair value: price $1.53, fair value $1.04, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HIND?
No. The price is what the market pays today ($1.53); the fair value is what the company's own numbers justify ($1.04). For Vyome Holdings the two are $0.4900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vyome Holdings worth?
The market values Vyome Holdings at about $10.7M (market capitalisation, as of Nov 15, 2026). Per share that is $1.53; our models calculate a fair value of $1.04 per share.
What do the bullish and bearish scenarios say about HIND?
Our models span a range for Vyome Holdings: cautious scenario $0.7800, base $1.04, optimistic $1.30 per share (as of Nov 15, 2026, price $1.53). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HIND?
Vyome Holdings trades at a price-to-earnings ratio of 0.9 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $1.04 is built from several models across several years. Other multiples: P/B 4.4, P/S 70.1.
How solid is the balance sheet of Vyome Holdings (HIND)?
Balance-sheet figures for Vyome Holdings (as of Nov 15, 2026): return on equity −74.8%. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is HIND from its 52-week high?
Vyome Holdings trades at $1.53, about 73% below its 52-week high of $5.73 and at the low of $1.53 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $1.04 is for.
Which stocks are comparable to Vyome Holdings?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vyome Holdings stock attractive at the current price?
The data as of Nov 15, 2026: price $1.53, calculated fair value $1.04 (−32%), Quality Score 22/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Vyome Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vyome Holdings (HIND)?
The closing price on Nov 16, 2026 was $1.53. Our estimate is $1.04, about 32% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vyome Holdings right now?
The price sits above even our optimistic bull case ($1.30). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Vyome Holdings

How large is the market capitalisation of Vyome Holdings (HIND)?
The market capitalisation of Vyome Holdings is $10.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vyome Holdings (HIND)?
The price-to-sales ratio of Vyome Holdings is 72.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vyome Holdings (HIND)?
Earnings per share at Vyome Holdings are $1.78 (price ÷ EPS = P/E 0.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Vyome Holdings (HIND)?
The return on equity (ROE) of Vyome Holdings is −74.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vyome Holdings (HIND)?
On an EBIT basis the return on assets of Vyome Holdings is −138% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vyome Holdings (HIND)?
The operating margin of Vyome Holdings is −2,854% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vyome Holdings (HIND)?
Revenue at Vyome Holdings is growing 67.5% versus a year earlier (3y avg −69.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Vyome Holdings (HIND) generate?
The free cash flow of Vyome Holdings is −$3.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Vyome Holdings (HIND) hold?
Vyome Holdings holds more cash than debt, $5.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Vyome Holdings in the live analysis

One click puts Vyome Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.